Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.43 |
| ▸ | DRD3 | P35462 | 10/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.39 |
| ▸ | DRD4 | P21917 | 3/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10049622 | 0.95 | SIGMAR1 (0.42) | DRD2DRD3ALDH1A1HRH3CCR2 | |
| SCHEMBL10049330 | 0.95 | SIGMAR1 (0.42) | DRD2DRD3ALDH1A1HRH3CCR2 | |
| SCHEMBL13134962 | 0.90 | DRD4 (0.43) | DRD2ALDH1A1HRH3CCR2DRD4 | |
| SCHEMBL13134919 | 0.90 | DRD4 (0.43) | DRD2ALDH1A1HRH3CCR2DRD4 | |
| SCHEMBL13876566 | 0.89 | ESR1 (0.41) | DRD2DRD3ALDH1A1HRH3CCR2 | |
| SCHEMBL11980190 | 0.88 | CNR1 (0.42) | DRD2DRD3ALDH1A1CCR2DRD4 | |
| SCHEMBL11958313 | 0.88 | CNR1 (0.42) | DRD2DRD3ALDH1A1CCR2DRD4 | |
| SCHEMBL13134878 | 0.87 | DRD2 (0.49) | DRD2DRD3ALDH1A1HRH3CCR2 | |
| SCHEMBL13440367 | 0.86 | ALDH1A1 (0.48) | ALDH1A1CCR2DRD4SIGMAR1 | |
| SCHEMBL11957744 | 0.84 | CNR1 (0.42) | CCR2DRD4SIGMAR1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249144-A1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | INTERVET INTERNATIONAL B.V. (NL) | 2010-09-30 | — | — | US | disclosed |
| US-20100249144-A1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | INTERVET INTERNATIONAL B.V. (NL) | 2010-09-30 | — | — | US | disclosed |
| WO-2009005645-A1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | SCHERING CORPORATION (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249144-A1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | CNR1, CNR2, GPR119 | DRD2 154/4885DRD3 400/4885ALDH1A1 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.